Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 29, 2021
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
[ Tue, Jun 29th 2021
] - WOPRAI
Mon, June 28, 2021
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
[ Mon, Jun 28th 2021
] - WOPRAI
Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $140 on, Jun 28th, 2021
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $176 to $140 on, Jun 28th, 2021.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $125 on, Wednesday, June 23rd, 2021
- Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
